Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15519348 | 0.80 | BAZ2B (0.44) | GSK3BBAZ2BHDAC8HDAC6HDAC2 | |
| SCHEMBL14511473 | 0.77 | F10 (0.45) | GSK3BBAZ2BHDAC8HDAC6HDAC2 | |
| SCHEMBL2982713 | 0.76 | GSK3B (0.57) | GSK3BGPR35ALDH1A1NPSR1POLB | |
| SCHEMBL4584130 | 0.73 | GSK3B (0.59) | GSK3BGPR35POLB | |
| SCHEMBL27447830 | 0.71 | GSK3B (0.61) | GSK3BGPR35 | |
| SCHEMBL27708243 | 0.71 | GSK3B (0.68) | GSK3BGPR35NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8572414 | 0.71 | BAZ2B (0.46) | GSK3BBAZ2BHDAC8HDAC6HDAC2 | |
| SCHEMBL7041123 | 0.70 | GSK3B (0.55) | GSK3BGPR35 | |
| SCHEMBL6784082 | 0.68 | GSK3B (1.00) | GSK3BGPR35ALDH1A1MAPT | |
| SCHEMBL14511472 | 0.68 | BAZ2B (0.44) | BAZ2BHDAC8HDAC6HDAC2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160030446-A1 | PYRIDO [4,3-B]INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9199985-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9187471-B2 | Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140296209-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140155384-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20130190293-A1 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-07-25 | — | — | US | disclosed |
| WO-2012112962-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-08-23 | — | — | WO | disclosed |
| WO-2012112963-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-08-23 | — | — | WO | disclosed |
| WO-2011103430-A1 | PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190293-A1 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | HTR4, HTR3B, HTR2C | GSK3B 102/4885BAZ2B 1528/4885HDAC8 4068/4885 |
| US-20140296209-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | GSK3B 832/4885BAZ2B 573/4885HDAC8 2225/4885 |
| US-20140155384-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | ADRB2, ADRA2C, ADRA2B | GSK3B 893/4885BAZ2B 864/4885HDAC8 3135/4885 |
| US-20160030446-A1 | PYRIDO [4,3-B]INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | HTR4, HTR3B, HTR2C | GSK3B 102/4885BAZ2B 1528/4885HDAC8 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.